Finance entity
earnings is the sole category represented across all 1 tracked stories. Assertio Holdings is most often covered alongside Perspective Therapeutics, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Assertio Holdings is most often covered alongside Perspective Therapeutics, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. We currently track 1 Finance story that mention Assertio Holdings, all published on March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 78 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Assertio Holdings. Shared-story counts are live from our verified record — not editorial picks.
Perspective Therapeutics and Assertio Holdings are preparing to release their Q4 2025 financial results, highlighting a critical juncture for both the radiopharmaceutical biotech and specialty pharma sectors. Investors are focused on clinical trial milestones for Perspective and portfolio optimization strategies for Assertio.
Assertio Holdings is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
